EBS$8.15
$8.23
Chart
Performance
Key Stats
AI EBS Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
HoldEmergent BioSolutions (EBS) presents a mixed investment profile. While its core business addresses significant public health threats, recent financial performance and current technical indicators suggest a cautious approach. Its valuation metrics are not immediately compelling at current levels, making it a potential hold for investors comfortable with its specific market and risks.
Thematic
Emergent BioSolutions operates in a critical niche addressing public health threats, including biodefense and infectious diseases. The demand for its products is driven by government contracts and public health initiatives, which can provide stable revenue streams. However, the company faces regulatory risks and challenges related to product development and commercialization.
Fundamental
Emergent BioSolutions' financials show a challenging recent performance with negative net income and declining revenue in certain periods. While there's a significant improvement in free cash flow in the latest reported quarter, the overall trend and profitability metrics require careful monitoring. The balance sheet indicates a substantial debt load relative to its market capitalization.
Technical
The stock is experiencing a significant downtrend, trading well below its 52-week high and showing weak momentum across various timeframes. Technical indicators suggest a bearish bias, with multiple moving averages acting as resistance.
| Factor | Score |
|---|---|
| Public Health Preparedness | 85 |
| Government Contracts & Dependence | 50 |
| Biotechnology Innovation | 65 |
| Regulatory Environment | 40 |
| Market Demand | 75 |
| Factor | Score |
|---|---|
| Valuation | 60 |
| Profitability | 40 |
| Growth | 30 |
| Balance Sheet Health | 30 |
| Cash Flow | 70 |
| Factor | Score |
|---|---|
| Trend Analysis | 20 |
| Momentum | 50 |
| Volume Confirmation | 40 |
| Support & Resistance | 50 |
| Short-Term Indicators | 40 |
AI Investing Checklist
Powered by LiveAIBullish Points (6)
Positive EPS Surprises
Emergent BioSolutions Inc. has shown positive earnings surprises in recent quarters, with reported EPS exceeding estimates by significant margins in Q4 2024 (+878.57%) and Q2 2024 (+168.6%). [11]
Low Price-to-Sales Ratio
The trailing Price-to-Sales (P/S) ratio is 0.6, indicating potential undervaluation relative to its revenue generation capabilities. [23]
Bearish Points (8)
Significant EPS Misses
Emergent BioSolutions Inc. has reported substantial EPS misses in several quarters, such as Q3 2024 (-$2.32 actual vs. -$0.94 estimate) and Q2 2023 (-$3.17 actual vs. -$1.24 estimate), indicating earnings volatility and unpredictability. [11]
Negative Earnings Per Share (EPS)
The EPS (TTM) is negative at -$2.58, which can make traditional P/E ratio analysis difficult and suggests underlying profitability issues. [4]
Calendar
August 2025
7
Next Earnings Date
H: $-0.72
A: $-0.72
L: $-0.72
H: 192.10M
A: 146.37M
L: 105.00M
Profile
Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; Botulism Antitoxin Heptavalent for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Trobigard, an atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.
Seasonals
Price Target
13.50 USD
The 39 analysts offering 1 year price forecasts for EBS have a max estimate of 15.00 and a min estimate of 12.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 95
Direct competitor in smallpox medical countermeasures with TPOXX, a key product area for EBS.
Weight: 90
Develops vaccines and adjuvants, including those with biodefense applications (e.g., anthrax vaccine candidates).
Weight: 90
Develops oral pill vaccines for infectious diseases (e.g., COVID-19, norovirus, influenza) and had a CDMO partnership with EBS.
Weight: 90
Specializes in vaccines for infectious diseases, notably smallpox and monkeypox, directly overlapping with EBS's MCM focus.